

1 **Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-**
2 **sampled and quarantined community after a COVID-19**
3 **outbreak - the CoNAN study**

4
5 Sebastian Weis^{1,2,3} André Scherag⁴, Michael Baier⁵, Michael Kiehntopf⁶, Thomas Kamradt⁷,
6 Steffi Kolanos¹, Juliane Ankert¹, Stefan Glöckner⁵, Oliwia Makarewicz¹, Stefan Hagel¹,
7 Christina Bahrs^{1,8}, Aurelia Kimmig¹, Hans Proquitté⁹, Joel Guerra^{1,2}, Bettina Löffler⁵, Mathias
8 W. Pletz¹ and the CoNAN study group.

9
10 ¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena,
11 Germany

12 ² Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany

13 ³ Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany

14 ⁴ Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena,
15 Germany

16 ⁵ Institute of Medical Microbiology, Jena University Hospital, Jena, Germany

17 ⁶ Institute of Clinical Chemistry and Laboratory Diagnostics and Integrated Biobank
18 Jena (IBBJ), Jena University Hospital, Jena, Germany

19 ⁷ Institute of Immunology, Jena University Hospital, Jena, Germany

20 ⁸ Department of Medicine I, Division of Infectious Diseases and Tropical Medicine,
21 Medical University of Vienna, Vienna, Austria

22 ⁹ Children's Hospital, Jena University Hospital, Jena, Germany

23
24
25
26 Number of words: 3.294

27 Number of tables: 2

28 Number of figures: 4

29 Number of references: 30

30
31 **Study Group**

32 Technische Universität Ilmenau, Ilmenau, Germany: Thomas Hotz

33 Local Cooperation partners: Petra Enders, Renate Koch, Steffen Mai, Matthias Ullrich

34
35 Thuringian state office for consumer protection, Bad Langensalza, Germany: Dagmar Rimek.

36
37 Institute of Clinical Chemistry and Laboratory Diagnostics and Integrated Biobank Jena
38 (IBBJ), Jena, Germany: Cora Richert, Cornelius Eibner, Bettina Meinung, Kay Stötzer, Julia
39 Köhler.

40
41 Children's Hospital, JUH, Jena, Germany: Hans Cipowicz, Christine Pinkwart

42
43 Department of Anesthesiology and Intensive Care Medicine, JUH, Jena, Germany: Michael
44 Bauer, Petra Dickmann, Annika Licht, Juliane Scholz, Wibke Wetzker.

45

Weis S. *et al.*

CoNAN

1 Institute for Infectious Disease and Infection Control, JUH, Jena, Germany: Anita Hartung,
2 Daniel Weiss, Lara Thieme, Gabi Hanf, Clara Schnizer, Jasmin Müller, Jennifer Kosenkow,
3 Franziska Röstel
4
5 Institute of Immunology, JUH, Jena, Germany: Nico Andreas, Raphaela Marquardt
6
7 Institute of Medical Microbiology, JUH, Jena, Germany: Stefanie Deinhardt-Emmer, Sebastian
8 Kuhn

9

10

11

12 **Corresponding Author:**

13

14 Mathias W. Pletz, MD

15 Sebastian Weis, MD

16 Institute for Infectious Diseases and Infection Control

17 Am Klinikum 1

18 Jena University Hospital

19 07747 Jena, Germany

20

21 Tel: +49.3641.9-324794

22 Fax: +49.3641.9-324652

23 Mail: Mathias.Pletz@med.uni-jena.de; Sebastian.Weis@med.uni-jena.de

24

25

26 **Keywords:** SARS-CoV-2, antibody response, immunity, quarantine

27

1 **ABSTRACT**

2 **Background:** Due to the substantial proportion of asymptomatic and mild courses many
3 SARS-CoV-2 infections remain unreported. Therefore, assessment of seroprevalence may
4 detect the real burden of disease. We aimed at determining and characterizing the rate of
5 SARS-CoV-2 infections and the resulting immunity in a defined population.

6 **Methods:** CoNAN is a population-based cohort study in the previously quarantined
7 community Neustadt-am-Rennsteig, Germany six weeks after a SARS-CoV-2 outbreak with
8 49 cases identified by PCR screening of all 883 inhabitants. The primary objective of the
9 study was to assess SARS-CoV-2 antibody seroconversion rate using six different IgG
10 detecting immunoassays. Secondary objectives of the study were: *i.*) to determine the rate of
11 seroconversion in children; *ii.*) to determine potential risk factors for symptomatic vs.
12 asymptomatic Covid19 courses; *iii.*) to investigate the rate of virus persistence.

13 **Findings:** We enrolled 626 participants (71% of the community population). All actual SARS-
14 CoV-2 PCR tests were negative; while a total of 8.4% (52 of 620 tested) had antibodies
15 against SARS-CoV-2 in at least two independent tests. Twenty of the antibody positive
16 participants had previously a positive SARS-CoV-2 PCR. On the contrary, of those 38
17 participants with SARS-CoV-2 infection, only 20 (52.6%) were antibody positive.

18 **Interpretation:** Several antibody tests conducted six weeks after an outbreak of SARS-CoV-2
19 did not detect all previously PCR-positive tested individuals. Cautious evaluation of antibody
20 testing strategies to assess immunity against the infection is warranted.

21 **Funding:** CoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and
22 Digital Society (TMWWDG).

23

24

25

26

27

28

1 INTRODUCTION

2 SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is an emerging pandemic
3 pathogen transmitted by smear, droplet and fomite infection ^{1,2}. There are neither vaccines
4 nor specific therapies currently available. The rate of asymptomatic infections is unclear and
5 most of the symptomatic cases take a mild course. However, approximately 15% of the
6 patients and especially older individuals develop a severe disease, *i.e.* progressive
7 pneumonia and multi-organ failure that is associated with increased mortality ^{1,3}.

8 Non-medical measures to prevent the spread of SARS-CoV-2 are currently based on the
9 interruption of infection chains through “social distancing”, public masking, school closure and
10 reduction of public life (“lockdown”). These have proven to be effective ⁴, yet, they are also
11 associated with substantial social and economic impact. Therefore, a “lockdown”- approach
12 will only be accepted by the societies as long as the advantages, *i.e.* protection of those most
13 vulnerable to severe courses of the disease surpass its associated disadvantages ⁵.
14 However, it needs to be taken into account that an early “exit” out of the lockdown is likely to
15 be associated with increasing infection rates that could result in a “second wave of infection”.
16 Hence, the consequences of such a “lockdown exit”, will depend on the extent of the
17 population that remains vulnerable to severe disease courses. It has been argued, that the
18 risk to acquire the infection is minimized if a large percentage of the population has been
19 infected with SARS-CoV-2 and has, at least partially, developed immunity against it ⁶, which
20 is referred to as herd immunity ⁵. Several population-based cohort studies have therefore tried
21 to determine the proportion of infected persons by measuring the sero-prevalence of anti-
22 SARS-CoV2 antibodies. Most of these studies have used only one or two different antibody
23 assays and omitting infants, whom to include is a challenge in such studies. The largest bias
24 of sero-prevalence studies is probably caused by the antibody assays used. Methodology
25 papers have shown that there are tremendous differences between the currently available
26 SARS-CoV-2 antibody assays with a test specificity ranging from 84.3-100% in pre-COVID-19
27 specimens and inter-test agreements ranged from 75.7-94.8% ^{7,8}.

28 To address some of the constraints, we aimed at determining and characterizing the rate of
29 SARS-CoV-2 infections and the resulting immune responses in a defined population. We
30 chose a population-based approach including infants and used six different IgG antibody
31 assays in parallel. The study was conducted in Neustadt-am-Rennsteig, a village in the Ilm
32 district in central Thuringia, Germany with 883 inhabitants in which a SARS-CoV-2 outbreak
33 had occurred. On March 22nd, 11 confirmed Covid-19 cases had been diagnosed in the
34 district of which 6 (55%) were Neustadt residents with further 69 residents classified as
35 contact persons. As a consequence, local public health authorities declared a 14-day
36 quarantine on the entire village in which residents were also not allowed to leave the village.
37 With support of the local family physician, an outbreak containment team of the public health
38 department conducted a mandatory mass screening using nasopharyngeal swabs starting on
39 April 1st in which 865 SARS-CoV-2 PCR tests were performed resulting in the diagnosis of
40 overall 49 SARS-CoV-2 infections. With the initiated containment measures, the outbreak was
41 controlled and the transmission to neighboring villages was prevented. There were three
42 SARS-CoV-2 associated deaths. Due to the isolated location of the village and the clear and
43 controlled outbreak, Neustadt-am-Rennsteig is well suited to study the sero-conversion and
44 immunity of SARS-CoV-2 infections.

45

46 METHODS

47 Study design and enrollment

48 The CoNAN study (Covid-19 outbreak in Neustadt-am-Rennsteig) is an ongoing exploratory
49 population-based cohort study. We here report the baseline characteristics of the participants
50 at the time of the outbreak/quarantine initiation and at study initiation. Follow-up assessments
51 are planned after 6 and 12 months relative to baseline assessment. All households in the

1 community of Neustadt-am-Rennsteig were informed by mail prior to study initiation about the
2 aims of study. Study participation is voluntary and can be withdrawn at any time, refusal to
3 participate has no consequences. Participants were enrolled from May 12th to 16th 2020 at a
4 central study site that was set-up in the villages' town hall and additional until May 22nd by
5 home visits. After informed consent, questionnaires, blood samples and pharyngeal washes
6 were directly taken at the study site. Pediatricians were part of the study team to adequately
7 involve under-aged participants and to ensure their appropriate sampling as well. At the study
8 site, plasma was directly centrifuged at 4°C/2,000 *g* for 10 minutes and stored at 8°C.
9 Pharyngeal washes were obtained after a short mouth wash with non-sparkling water under
10 direct supervision of a study team member to ensure appropriate quality. Samples were
11 transported twice a day to the Jena University Hospital allowing a timely further processing at
12 the participating research institutes. Participants who could not come to the study site were
13 enrolled by the local primary care physician at their respective homes until the 22nd of May.

14 **Ethics review, data protection and data management**

15 The study was conducted according to the current version of the Declaration of Helsinki and
16 has been approved by the institutional ethics committees of the Jena University Hospital and
17 the respective data protection commissioner (approval number 2020-1776) and the ethics
18 committee of the Thuringian chamber of physicians. All data were collected with unique
19 pseudonyms on paper case report forms. These identifiers were later used to merge the
20 questionnaire information with the laboratory information in an electronic study database.
21 Study registrations was applied at the German Clinical Trials Register: DRKS00022416.

22 **Inclusion Criteria**

23 All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or
24 infections status were eligible for participation. Informed consent was provided by the
25 participants or the parents/legal representatives.

26 **Exclusion Criteria**

27 Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community
28 of Kahlert were not eligible for inclusion.
29

30 **Objectives and outcomes**

31 The primary objective was to determine the SARS-CoV-2 antibody status (sero-conversion
32 rate) of the population of Neustadt-am-Rennsteig with a defined distance to the end of the
33 quarantine period. SARS-CoV-2 antibody status was defined as "positive" if participants had a
34 positive test result in ≥ 2 of the six antibody tests (details below); otherwise participants were
35 classified as "negative". The secondary objectives of the study were: *i.*) to determine the rate
36 of seroconversion in children; *ii.*) to determine potential risk factors for symptomatic vs.
37 asymptomatic Covid19 courses; *iii.*) to investigate the rate of virus persistence (as part of
38 future follow-up assessments).

39 **Questionnaire**

40 Participants completed a pseudonymized questionnaire directly at the study site. Clusters
41 were reconstructed using the family name, address and information of household members
42 as provided in the questionnaire. After re-assessing the original paper case report forms,
43 obvious errors were corrected, and duplicated entries were deleted. Plausibility checks of
44 demographic data were performed. Symptoms were noted if reported. Strength and duration
45 of symptoms was not weighted in the analysis of this manuscript. Self-reported information on
46 a positive SARS-CoV-2 PCR test at the time point of the outbreak/quarantine initiation was
47 double-checked with the information by the health department of the IIm-district if the
48 participants gave their permission on the consent form.

1 **SARS-CoV-2 RT-PCR**

2 Detection of SARS-CoV-2 in pharyngeal wash samples was performed by RT-PCR
3 amplification of SARS-CoV-2 E-gene and S-gene fragments. 200 μ L of the pharyngeal
4 washes were first processed for RNA extraction in the InnuPure C16 using the innuPREP
5 virus DNA/RNA kit (both: Analytik Jena, Jena, Germany). Subsequently, the detection of E-
6 and S-gene of SARS-CoV-2 was performed by using the RealStar SARS-CoV-2 RT-PCR kit
7 1.0 (Altona Diagnostics, Hamburg, Germany) on a Rotor-Gene Q real-time PCR cyclor
8 (Qiagen, Hilden, Germany). The amplification protocol consisted of a reverse transcription
9 step at 55°C for 20 minutes, a denaturation step at 95°C for 2 minutes and subsequent 45
10 cycles at 95°C/55°C/72°C for 15/45/15 seconds, respectively. A positive result was defined as
11 amplification of E- and S-gene in a sample with each cycle threshold value (ct) less than 37.
12 Results from apparently inhibited samples with insufficient internal controls (ct > 37) were
13 verified by using a second RT-PCR test. For these samples, RNA was once again extracted
14 from the original pharyngeal wash specimens via QIASymphony using the QIASymphony
15 DSP Virus/Pathogen MiniKit (Qiagen) according to manufacturer's instructions. Subsequently,
16 the RT-PCR step was performed on a LightCycler 480 II (F. Hoffmann-La Roche AG, Basel,
17 Switzerland) using the LightMix Modular Sarbecovirus E-gene kit (TIB MOLBIOL, Berlin,
18 Germany). All steps were performed according to the manufacturer's instructions.

19

20 **SARS-CoV-2 antibody testing**

21 Detection of SARS-CoV-2 IgG antibodies was performed with six different quantification
22 methods, of which two were enzyme-linked immunosorbent assays (ELISA) and four were
23 chemiluminescence-based immunoassays (CLIA/CMIA). In addition, a lateral flow assay
24 (combined IgG/IgM), one IgA (ELISA) and two IgM immunoassays (ELISA and CLIA) were
25 performed that in this setting cannot be directly compared to the IgG immunoassays and will
26 therefore not be reported in this manuscript. All tests were carried out according to
27 manufacturers' instructions. For detailed information on assay characteristics and instruments
28 used see [Supplementary Table 1](#). Sensitivities and specificities are shown as provided by the
29 manufacturer. The following assays were used; EDI Novel Coronavirus SARS-CoV-2 IgG
30 ELISA kit (Epitope Diagnostics Inc., San Diego, USA), SARS-CoV-2 IgG ELISA kit
31 (Euroimmun, Lübeck, Germany), SARS-CoV-2 S1/S2 IgG CLIA kit (DiaSorin, Saluggia, Italy),
32 2019-nCoV IgG kit (Snibe Co., Ltd., Shenzhen, China), SARS-CoV-2 IgG CMIA kit (Abbott,
33 Chicago, USA) and Elecsys Anti-SARS-CoV-2 kit (Roche, Basel Switzerland).

34

35 **Statistical Analysis**

36 **Sample size considerations**

37 The samples size of the CoNAN-cohort is fixed by the number of inhabitants (n=883) of the
38 community of Neustadt-am-Rennsteig. We aimed at including the population as completely as
39 possible. In addition, we consulted the WHO population-based age-stratified sero-
40 epidemiological investigation protocol for SARS-CoV-2 infection ⁹. On the basis of this
41 recommendation, we estimated that a study with 600 samples (*i.e.* an inclusion rate of about
42 70%) should be sufficient to estimate a (true) seroconversion rate <10%/<20% with an
43 expected margin of error of $\pm 3\%/\pm 4\%$ (defined by the expected width in percent points of the
44 95% confidence interval for the seroconversion point estimate using "Confidence interval for
45 proportion using normal approximation (n large)" of nQuery 4.0).

46

47 **Data analysis**

48 All statistical analyses were performed in the analysis population sometime stratified by age
49 (adults/children and adolescents) and sero-status from the serological tests. Descriptive
50 analyses included the calculation of mean with standard deviation (SD) and medians with
51 minimum and maximum values for continuous variables, and absolute counts (n, with
52 percentages) for categorical variables. Owing to the great data completeness, we performed

1 no data imputations. As inferential statistics, we applied logistic regression models exploring
2 the associations between the participant-reported symptoms, the SARS-CoV-2 PCR-results
3 of the initial mass testing and the binary serostatus outcome. To adjust estimates for cluster
4 effects between participants living in the same household (derived from their address
5 information) we applied generalized estimation equations (GEE) with exchangeable
6 correlation structure and logistic link function. In addition, we adjusted some of the models for
7 sex and age (linear). Results of logistic GEE models are presented as odds ratio (OR) point
8 and interval estimates. Results are presented such that $OR > 1$ indicate increasing odds for a
9 sero-positive finding with increasing exposures. All confidence intervals (CI) were calculated
10 with 95% coverage. CIs are Wald CIs that are not adjusted for multiple comparisons.
11 Similarly, all reported p-values are unadjusted and two-sided. Due to the explorative nature of
12 the study, we avoided “statistical significance testing”. We used the R Language for Statistical
13 Computing (version 4.0.2; R Core Team 2019: R: A Language and Environment for Statistical
14 Computing. R Foundation for Statistical Computing, Vienna, Austria) for all analyses.

17 RESULTS

18 Participant characteristics

19 A total of 626 of the 883 inhabitants (71%) participated in the study. Pharyngeal washes were
20 obtained from 617 (98.6 %) participants at the time of the inclusion. All PCR tests were
21 negative. Plasma samples were obtained from a total of 620 (99%) participants who define
22 the analyzed sample cohort. Of those 620 analyzed participants, 58 (9%) were adolescents
23 and children (<18 years of age at inclusion) and 36 (6%) of these were 12 years of age or
24 younger. [Figure 1](#) shows a flow-chart of the CoNAN study. Characteristics of the participants
25 are given in [Table 1](#) and [Supplementary Figure 1](#). In four participants the results of the initial
26 PCR-testing during the outbreak could not be revealed. None of these had anti-SARS-CoV2
27 antibodies.

28 All six serological tests were performed in 600 (96%) participants. In the remaining 20
29 individuals (4%), five tests were used for final analysis because, either there was limited
30 material available or the results were inconclusive in one out of the six tests. A comparative
31 performance of the tests is shown in [Figure 2](#). In 610 participants, pharyngeal washes and
32 serological test were performed. Upset Plot showing the comparison of test performance
33 between the six serological IgG tests used to evaluate the antibody response in the CoNAN
34 study

36 Antibody tests

37 We found that 52/620 (8.4%) participants had anti-SARS-CoV-2 IgG antibodies of which 20
38 had been test positive by PCR during the prior sampling at the SARS-CoV-2 outbreak ([Figure](#)
39 [3A](#); [Table 1,2](#)). Among the antibody-positive participants, there was one child. Therefore,
40 approximately six weeks after proven SARS-CoV-2 infection, antibodies were only detectable
41 in 38.5% participants. Twelve participants with PCR-proven SARS-CoV-2 infection had no
42 symptoms consistent with a respiratory infection or sickness during the last two months, while
43 180 PCR-negative participants and 168 antibody-negative participants reported respiratory
44 symptoms during the same period, potentially reflecting common respiratory infections in
45 springtime ([Figure 3B](#)). Thirteen of the 52 seropositive participants (25%) did not report any
46 symptoms of the SARS-CoV-2 infection ([Figure 3C](#)). Interestingly, two of them; a 55-year old
47 male and a 73-year old male had been tested positive for SARS-CoV-2 infection. In 26
48 participants, only one out of six serologic tests returned positive. These patients were judged
49 to reflect uncertain cases and assessed as sero-negative for the comparison shown in [Figure](#)
50 [3](#). Three of these had previously been tested positive for SARS-CoV-2 infection.

51

1 **Antibody tests and self-reported symptoms**

2 *Figures 3B,C* display a summary of the self-reported symptoms that basically summarizes
3 any of the 14 questions related to symptoms into one variable, *Figure 4* is a more detailed
4 depiction at individual symptoms in all participants (*Figure 4A*) or stratified by the initial SARS-
5 CoV-2 PCR-results (*Figure 4B,C*). Loss of smell and taste were the best predictors of later
6 seropositivity irrespective of stratification with odds ratios point estimates ≥ 10 . Interestingly,
7 in individuals that knew they were initially PCR negative, perceived muscle and joint pain,
8 sweats and chills, shortness of breath or fatigue turned out to be predictors of later
9 seropositivity as well. All three investigated variables were strongly associated with OR of
10 17.37 (95%-CI 8.10-37.24) for PCR vs. antibody status, an OR of 6.33 (95%-CI 2.84-14.11)
11 for PCR vs. any reported symptom and an OR of 8.71 (95%-CI 4.02-18.89) for antibody
12 status vs. any reported symptom, respectively.
13
14

15 **DISCUSSION**

16 We performed a population-based cohort study enrolling 71% of the population of a central-
17 German village six weeks after a SARS-CoV-2 outbreak with subsequent community
18 quarantining. Our data shows strikingly lower number of seropositive participants than we had
19 expected based on the initial mass screening and the estimates of asymptomatic infections
20 previously reported^{10 11 12}. Only 8.4% of the tested population were seropositive for anti
21 SARS-CoV-2 antibodies in which 6.2% (38/610) had proven SARS-CoV-2 infection, indicating
22 a low rate of asymptomatic cases.

23 It is currently unknown why in some patients with previously PCR-proven SARS-CoV-2
24 infection we cannot detect specific antibodies. It has been suggested that less severe clinical
25 manifestations might be associated with lower or absent antibody titers¹³. However, there are
26 also reports on asymptomatic subjects in whom neutralizing, specific antibodies against
27 SARS-CoV-2 are being found¹⁴. Another possibility is that the antibodies were produced, but
28 that the antibody titers declined rapidly, especially as waning of specific antibodies after
29 infection is a common feature observed in corona virus infections^{15,16}. Also, recent data by
30 Long *et al.* suggests that asymptomatic patients might develop weaker immunity against
31 SARS-CoV-2 infection as indicated by an early decrease of IgG and neutralizing antibodies¹⁷.
32 Whether the low rate of seroconversion reflects early waning or whether these individuals in
33 fact did not develop antibodies that could be detected with the applied tests, remains to be
34 speculative.

35 Our post-outbreak seroprevalence cohort studies differs from similar studies^{11,18} first by the
36 “complete” cohort approach including children and infants instead of a representative sample
37 and second by the extensive use of different antibody assays. An outbreak, similar in median
38 age (58 years) and quarantine measures occurred on the Diamond Princess cruise ship¹⁸. In
39 this outbreak, of 3,711 exposed people, there were 619 confirmed SARS-CoV-2 infections
40 corresponding to 17% of which 318 were symptomatic at the time of and 301 had symptoms
41 before testing¹⁸ (*Table 1*). The infection fatality rate was estimated to be 1.3% (95% CI 0.38-
42 3.6) and the case fatality rate twice higher (2.6%; 95% CI 0.89-6.7) reflecting the 50% of
43 asymptomatic cases. Of note, case- and infection mortality rate dramatically increased in
44 patients of 70 years and older. No data on antibody testing is available for this cohort.
45 Rocklöv *et al.* modeled the effectiveness of infection control measures and suggested that the
46 early intervention prevented 2,000 additional cases¹⁹.

47 Most patients develop antibodies against SARS-CoV-2 within approximately one week after
48 infection¹³. Several investigators have reported 100% anti-SARS-CoV-2 IgG seropositivity in
49 patients or in convalescent individuals²⁰⁻²³. Using up to six different assays, we found that IgG
50 antibodies were detectable in 39/52 subjects who had had suggestive symptoms of COVID-
51 19 and in 20/38 participants with previously diagnosed SARS-CoV-2 infection. This confirms
52 and extends earlier studies, in which IgG against different SARS-CoV-2 antigens were not

1 detectable in a fraction of patients who were examined at least 14 days after disease onset or
2 convalescents^{11,22,24}. Whereas in some reports the lowest reported rate in convalescent
3 subjects was 77.9% (116/149 subjects) for anti-RBD-IgG and 69.8% (104/149) for anti-S-IgG
4 in a study from New York²⁴.

5 The significance of the finding that eight participants which reported a transient anosmia or
6 loss of taste that had not previously been tested positive and were antibody negative, remains
7 unclear. Also, the correlation between antibody titers and the level of protection currently is
8 also unknown. Potent neutralizing antibodies have been detected in patients with high or low
9 serum concentrations of antibodies measured by ELISA²⁴ and the level of neutralizing
10 antibodies has been reported to correlate with the number of SARS-CoV-2 specific T-cells²⁵.
11 The correlation between antibodies and protection against COVID-19 is further complicated
12 by evidence suggesting antibody-induced disease enhancement in other coronavirus
13 infections including SARS²⁶. All available evidence indicates that antibody responses alone
14 do not suffice to overcome SARS-CoV-2 infection. Data from SARS-CoV and MERS-CoV
15 suggest that T-cell responses are required for protection and may last longer than antibody
16 titers²⁶⁻³⁰. Consequently, we are currently analyzing the neutralization capacity in cell culture
17 systems and SARS-CoV-2 specific T-cell responses in our study participants.

18

19 **Limitations**

20 Our study has several limitations: *i.*) our study was a population-based cohort study. We were
21 able to recruit 71% of the community population. However, 29% of the population did not
22 participate for unknown reasons which could introduce a bias in the assessment; *ii.*) the study
23 was carried out six weeks after the end of the 14-day quarantine. This could have missed a
24 number of participants that had a rapidly waning antibody response and *iii.*) there was no
25 baseline of the antibody status before the quarantine as some participants might have been
26 exposed earlier during the pandemic.

27

28 **CONCLUSIONS**

29 Our data questioned the relevance and reliability of IgG antibody testing to detect past SARS-
30 CoV-2 infections six weeks after an outbreak. We conclude that assessing immunity for
31 SARS-CoV-2 infection should not only rely on antibody tests but might also include the
32 determination of neutralizing antibodies and potentially cellular immunity and requires long
33 term follow up studies.

34

34 **ABBREVIATIONS**

CI	confidence interval
GEE	generalized estimation equations
MERS-CoV	Middle East respiratory syndrome-related coronavirus
OR	odds ratio
SARS-CoV	severe acute respiratory syndrome-related coronavirus

35

36

37 **Funding:** CoNAN was funded by the Sondervermögen „Corona“ of the Thuringian Ministry for
38 Economic Affairs, Science and Digital Society (TMWWDG).

39

40 **Role of the Sponsor:** The funding agency had no role in the design and conduct of the study;
41 collection, management, analyses, and interpretation of the data; preparation, review, or
42 approval of the manuscript; and decision to submit the manuscript for publication.

43

44 **Competing interests:** None declared.

45

46 **Conflicts of Interest:** SW received speaker fees from MSD and Infectopharm. SH received

1 speaker fees from Pfizer, MSD and Astra Zeneca. **TK** speaker fees from Roche **MP** has
2 participated in international advisory boards from Pfizer, Novartis, Basilea and Cubist and
3 received speaker fees from the same companies. **CB** has participated in advisory boards
4 from GSK and received speaking fees from Pfizer. All other authors do not report any conflict
5 of interest.

6
7

8 **Acknowledgement**

9 The project is carried out in cooperation with the district administration and the health
10 department of the Ilm-district and is funded by the Thuringian Ministry for Economic Affairs,
11 Science and Digital Society (TMWWGD). We thank Heike Kiesewetter, Anett Büschel and
12 Luzie Rösel for technical assistance.

13

14 **REFERENCES**

15

- 17 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
18 coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
- 19 2. Whitworth J. COVID-19: a fast evolving pandemic. *Trans R Soc Trop Med Hyg* 2020;
20 **114**(4): 241-8.
- 21 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
22 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*
23 2020; **395**(10223): 507-13.
- 24 4. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination
25 with other public health measures to control COVID-19: a rapid review. *Cochrane Database*
26 *Syst Rev* 2020; **4**: CD013574.
- 27 5. Smith CE. Prospects for the control of infectious disease. *Proc R Soc Med* 1970;
28 **63**(11 Part 2): 1181-90.
- 29 6. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. *Immunity*
30 2020; **52**(5): 737-41.
- 31 7. Whitman JD, Hiatt J, Mowwery CT, et al. Test performance evaluation of SARS-CoV-
32 2 serological assay. *medRxiv preprint* 2020; **Version 2** (May 17).
- 33 8. Jaaskelainen AJ, Kuivanen S, Kekalainen E, et al. Performance of six SARS-CoV-2
34 immunoassays in comparison with microneutralisation. *J Clin Virol* 2020; **129**: 104512.
- 35 9. WHO-2019. [https://apps.who.int/iris/bitstream/handle/10665/331656/WHO-2019-](https://apps.who.int/iris/bitstream/handle/10665/331656/WHO-2019-nCoV-Seroepidemiology-2020.1-eng.pdf?sequence=1&isAllowed=y)
36 [nCoV-Seroepidemiology-2020.1-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/331656/WHO-2019-nCoV-Seroepidemiology-2020.1-eng.pdf?sequence=1&isAllowed=y). 2019.
- 37 10. Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of
38 Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. *JAMA* 2020; **323**(23): 2424-5.

- 1 11. Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2
2 infection in a German community with a super-spreading event. *medRxiv preprint* 2020;
3 **Version 2**(June 2).
- 4 12. Shields AM, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroconversion in
5 health care workers. *medRxiv preprint* 2020; **Version 1**(May 19).
- 6 13. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
7 mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and
8 association of antibody responses with severity of disease. *medRxiv Preprint* 2020; **Version 1**
9 (Apr 17).
- 10 14. Kraehling V, Kern M, Halwe S, et al. Epidemiological study to detect active SARS-
11 CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt
12 am Main metropolitan area. *medRxiv preprint* 2020; **Version 1**(May 25).
- 13 15. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune
14 response to experimental coronavirus infection of man. *Epidemiol Infect* 1990; **105**(2): 435-
15 46.
- 16 16. Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe
17 acute respiratory syndrome. *Emerg Infect Dis* 2007; **13**(10): 1562-4.
- 18 17. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of
19 asymptomatic SARS-CoV-2 infections. *Nat Med* 2020.
- 20 18. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality
21 ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the
22 Diamond Princess cruise ship, February 2020. *Euro Surveill* 2020; **25**(12).
- 23 19. Rocklöv J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess
24 cruise ship: estimating the epidemic potential and effectiveness of public health
25 countermeasures. *J Travel Med* 2020; **27**(3).
- 26 20. Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses
27 in COVID-19 patients. *Emerg Microbes Infect* 2020; **9**(1): 940-8.
- 28 21. Jiang HW, Li Y, Zhang HN, et al. Global profiling of SARS-CoV-2 specific IgG/ IgM
29 responses of convalescents using a proteome microarray. *Nat Commun* 2020; **11**(1): 3581.
- 30 22. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior
31 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-
32 2: an observational cohort study. *Lancet Infect Dis* 2020; **20**(5): 565-74.
- 33 23. Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in
34 Patients with COVID-19. *Clin Infect Dis* 2020; ciaa461.

- 1 24. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to
2 SARS-CoV-2 in convalescent individuals. *Nature* 2020. Jun 18.
- 3 25. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular
4 Immunity in COVID-19 Convalescent Individuals. *Immunity* 2020; **52**(6): 971-7 e3.
- 5 26. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the
6 Science. *Immunity* 2020; **52**(6): 910-41.
- 7 27. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine
8 development against MERS-CoV. *Antiviral Res* 2017; **137**: 82-92.
- 9 28. Chen J, Subbarao K. The Immunobiology of SARS*. *Annu Rev Immunol* 2007; **25**:
10 443-72.
- 11 29. Zhao J, Zhao J, Mangalam AK, et al. Airway Memory CD4(+) T Cells Mediate
12 Protective Immunity against Emerging Respiratory Coronaviruses. *Immunity* 2016; **44**(6):
13 1379-91.
- 14 30. Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in
15 recovered patients with severe acute respiratory syndrome: a six-year follow-up study. *J*
16 *Immunol* 2011; **186**(12): 7264-8.
- 17

1 **FIGURES AND TABLES**

2

3 **Figure 1:** Flow chart of the CoNAN study. * PCR from pharyngeal washes obtained during
4 the CoNAN study in May 2020.

5

6

7 **Figure 2:** Upset Plot showing the comparison of test performance between the six serological
8 IgG tests used to evaluate the antibody response in the CoNAN study.

9 **Abbreviations:** DS..SARS-CoV-2 S1/S2 IgG CLIA kit (DiaSorin, Saluggia, Italy); ED..EDI
10 Novel Coronavirus SARS-CoV-2 IgG ELISA kit (Epitope Diagnostics Inc., San Diego, USA);
11 EU..SARS-COV-2 IgG ELISA kit (Euroimmun, Lübeck, Germany); SN.2019-nCoV IgG kit
12 (Snibe Co., Ltd., Shenzhen, China).

13

14

15 **Figure 3:** Cross tables of A) antibody status vs. SARS-CoV-2 PCR-results (initial mass
16 testing);_B) symptoms vs. SARS-CoV-2 PCR-results (initial mass testing); C) symptoms vs.
17 antibody status. The estimated odds ratios for antibody status (A), any symptoms (B, C) are
18 derived from a logistic GEE model adjusted for sex and age (linear). Note that A) and B) are
19 limited to those 610 participants with an available initial mass-testing PCR-result.
20 Abbreviations: CI..confidence interval, OR..odds ratio.

21

22

23 **Figure 4:** Associations for reported clinical symptoms and positive antibody status for A) all
24 participants, B) previously SARS-CoV-2 PCR-positive and C) previously SARS-CoV-2 PCR-
25 negative. Odds ratio and corresponding 95% confidence interval are derived from the logistic
26 GEE model adjusted for household clustering and sex and age (linear); the plots display the
27 complete cases.

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

1 **Table 1:** Characteristics of the analyzed (*i.e.* with serum samples) 562 adult participants
 2 stratified by serostatus and the analyzed (*i.e.* with serum samples) 58 participating
 3 adolescents and children. Abbreviations: no..number; SD..standard deviation
 4

Characteristic	Adults			Children and adolescents
	Sero-negative (N=511)	Sero-positive (N=51)	Overall (N=562)	Overall (N=58)*
Size of household clusters				
1 person	84 (16.4%)	6 (11.8%)	90 (16.0%)	0 (0%)
2 persons	216 (42.3%)	31 (60.8%)	247 (44.0%)	0 (0%)
3 persons	108 (21.1%)	5 (9.8%)	113 (20.1%)	18 (31.0%)
4 persons	57 (11.2%)	7 (13.7%)	64 (11.4%)	32 (55.2%)
5+ persons	44 (8.6%)	1 (2.0%)	45 (8.0%)	5 (8.6%)
Missing	2 (0.4%)	1 (2.0%)	3 (0.5%)	3 (5.2%)
Sex - no.(%)				
Male	238 (46.6%)	28 (54.9%)	266 (47.3%)	35 (60.3%)
Female	273 (53.4%)	23 (45.1%)	296 (52.7%)	22 (37.9%)
Missing				1 (1.7%)
Age (years)				
Mean (SD)	57.9 (16.8)	60.3 (13.2)	58.1 (16.5)	9.62 (4.38)
Median [Min, Max]	60 [18, 97]	62 [24, 83]	60 [18, 97]	10 [1, 17]
PCR during quarantine (reported) - no.(%)				
negative	490 (95.9%)	31 (60.8%)	521 (92.7%)	51 (87.9%)
positive	16 (3.1%)	20 (39.2%)	36 (6.4%)	2 (3.4%)
not known	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	5 (1.0%)	0 (0%)	5 (0.9%)	5 (8.6%)
Chron. lung disease - no.(%)				
Yes	44 (8.6%)	3 (5.9%)	47 (8.4%)	2 (3.4%)
No	465 (91.0%)	48 (94.1%)	513 (91.3%)	52 (89.7%)
not known	1 (0.2%)	0 (0%)	1 (0.2%)	1 (1.7%)
Missing	1 (0.2%)	0 (0%)	1 (0.2%)	3 (5.2%)
Cardiovascular disease - no.(%)				
Yes	252 (49.3%)	24 (47.1%)	276 (49.1%)	0 (0%)
No	248 (48.5%)	26 (51.0%)	274 (48.8%)	58 (100%)
not known	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	11 (2.2%)	1 (2.0%)	12 (2.1%)	
Diabetes - no.(%)				
Yes	89 (17.4%)	5 (9.8%)	94 (16.7%)	0 (0%)
No	420 (82.2%)	45 (88.2%)	465 (82.7%)	55 (94.8%)
not known	2 (0.4%)	1 (2.0%)	3 (0.5%)	0 (0%)
Missing				3 (5.2%)
Cancer - no.(%)				
Yes	34 (6.7%)	1 (2.0%)	35 (6.2%)	0 (0%)
No	474 (92.8%)	50 (98.0%)	524 (93.2%)	55 (94.8%)
not known	3 (0.6%)	0 (0%)	3 (0.5%)	0 (0%)
Missing				3 (5.2%)
Autoimmune diseases / immune deficiency - no.(%)				
Yes	22 (4.3%)	3 (5.9%)	25 (4.4%)	0 (0%)
No	485 (94.9%)	47 (92.2%)	532 (94.7%)	55 (94.8%)
not known	4 (0.8%)	1 (2.0%)	5 (0.9%)	0 (0%)
Missing				3 (5.2%)

Weis S. *et al.*

CoNAN

Smoker - no.(%)				
No	335 (65.6%)	42 (82.4%)	377 (67.1%)	55 (94.8%)
Current smoker	122 (23.9%)	5 (9.8%)	127 (22.6%)	0 (0%)
Former smoker	52 (10.2%)	4 (7.8%)	56 (10.0%)	0 (0%)
Missing	2 (0.4%)	0 (0%)	2 (0.4%)	3 (5.2%)

*note that only one individual was characterized as "Sero-positive"

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

1 **Table 2:** Characteristics of the analyzed (*i.e.* with serum samples) 562 adult participants
 2 stratified by serostatus and the analyzed (*i.e.* with serum samples) 58 participating
 3 adolescents and children. Abbreviations: no..number; SD..standard deviation
 4

	Sero-negative (N=511)	Adults Sero-positive (N=51)	Overall (N=562)	Children and adolescents Overall (N=58)*
Have you been sick during the last 2 months?				
Yes	105 (20.5%)	32 (62.7%)	137 (24.4%)	14 (24.1%)
No	404 (79.1%)	18 (35.3%)	422 (75.1%)	41 (70.7%)
Missing	2 (0.4%)	1 (2.0%)	3 (0.5%)	3 (5.2%)
Loss of taste				
Yes	7 (1.4%)	20 (39.2%)	27 (4.8%)	0 (0%)
No	504 (98.6%)	31 (60.8%)	535 (95.2%)	55 (94.8%)
Missing				3 (5.2%)
Loss of smell				
Yes	6 (1.2%)	11 (21.6%)	17 (3.0%)	0 (0%)
No	505 (98.8%)	40 (78.4%)	545 (97.0%)	55 (94.8%)
Missing				3 (5.2%)
Fever				
Yes	23 (4.5%)	11 (21.6%)	34 (6.0%)	4 (6.9%)
No	488 (95.5%)	40 (78.4%)	528 (94.0%)	51 (87.9%)
Missing				3 (5.2%)
Headache				
Yes	0 (0%)	0 (0%)	0 (0%)	0 (0%)
No	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	511 (100%)	51 (100%)	562 (100%)	58 (100%)
Cough				
Yes	71 (13.9%)	24 (47.1%)	95 (16.9%)	8 (13.8%)
No	440 (86.1%)	27 (52.9%)	467 (83.1%)	46 (79.3%)
Missing				4 (6.9%)
Nose congestion				
Yes	67 (13.1%)	8 (15.7%)	75 (13.3%)	16 (27.6%)
No	442 (86.5%)	43 (84.3%)	485 (86.3%)	38 (65.5%)
Missing	2 (0.4%)	0 (0%)	2 (0.4%)	4 (6.9%)
Sore throat				
Yes	36 (7.0%)	11 (21.6%)	47 (8.4%)	10 (17.2%)
No	475 (93.0%)	40 (78.4%)	515 (91.6%)	45 (77.6%)
Missing				3 (5.2%)
Shortness of breath				
Yes	10 (2.0%)	9 (17.6%)	19 (3.4%)	0 (0%)
No	501 (98.0%)	42 (82.4%)	543 (96.6%)	55 (94.8%)
Missing				3 (5.2%)
Other respiratory symptoms				
Yes	9 (1.8%)	5 (9.8%)	14 (2.5%)	0 (0%)
No	502 (98.2%)	46 (90.2%)	548 (97.5%)	55 (94.8%)
Missing				3 (5.2%)
Fatigue				
Yes	46 (9.0%)	22 (43.1%)	68 (12.1%)	3 (5.2%)
No	465 (91.0%)	29 (56.9%)	494 (87.9%)	52 (89.7%)
Missing				3 (5.2%)

Weis S. *et al.*


CoNAN

Sweats and chills				
Yes	26 (5.1%)	14 (27.5%)	40 (7.1%)	5 (8.6%)
No	485 (94.9%)	37 (72.5%)	522 (92.9%)	50 (86.2%)
Missing				3 (5.2%)
Muscle and joint ache				
Yes	35 (6.8%)	16 (31.4%)	51 (9.1%)	3 (5.2%)
No	476 (93.2%)	35 (68.6%)	511 (90.9%)	52 (89.7%)
Missing				3 (5.2%)
Nausea, vomiting, stomach pain				
Yes	24 (4.7%)	8 (15.7%)	32 (5.7%)	6 (10.3%)
No	487 (95.3%)	43 (84.3%)	530 (94.3%)	49 (84.5%)
Missing				3 (5.2%)


*note that only one individual was characterized as "Sero-positive"

1
2


medRxiv preprint doi: <https://doi.org/10.1101/2020.07.15.20154112>; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](#).




medRxiv preprint doi: <https://doi.org/10.1101/2020.07.15.20154112>; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




A




B



C




A
 medRxiv preprint doi: <https://doi.org/10.1101/2020.07.15.20154112>; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



B

PCR-positive



C

PCR-negative

